Back to Search Start Over

CUL3-related neurodevelopmental disorder: Clinical phenotype of 20 new individuals and identification of a potential phenotype-associated episignature

Authors :
Liselot van der Laan
Ananília Silva
Lotte Kleinendorst
Kathleen Rooney
Sadegheh Haghshenas
Peter Lauffer
Yasemin Alanay
Pratibha Bhai
Alfredo Brusco
Sonja de Munnik
Bert B.A. de Vries
Angelica Delgado Vega
Marc Engelen
Johanna C. Herkert
Ron Hochstenbach
Saskia Hopman
Sarina G. Kant
Ryutaro Kira
Mitsuhiro Kato
Boris Keren
Hester Y. Kroes
Michael A. Levy
Ngu Lock-Hock
Saskia M. Maas
Grazia M.S. Mancini
Carlo Marcelis
Naomichi Matsumoto
Takeshi Mizuguchi
Alessandro Mussa
Cyril Mignot
Anu Närhi
Ann Nordgren
Rolph Pfundt
Abeltje M. Polstra
Slavica Trajkova
Yolande van Bever
Marie José van den Boogaard
Jasper J. van der Smagt
Tahsin Stefan Barakat
Mariëlle Alders
Marcel M.A.M. Mannens
Bekim Sadikovic
Mieke M. van Haelst
Peter Henneman
Source :
HGG Advances, Vol 6, Iss 1, Pp 100380- (2025)
Publication Year :
2025
Publisher :
Elsevier, 2025.

Abstract

Summary: Neurodevelopmental disorder with or without autism or seizures (NEDAUS) is a neurodevelopmental disorder characterized by global developmental delay, speech delay, seizures, autistic features, and/or behavior abnormalities. It is caused by CUL3 (Cullin-3 ubiquitin ligase) haploinsufficiency. We collected clinical and molecular data from 26 individuals carrying pathogenic variants and variants of uncertain significance (VUS) in the CUL3 gene, including 20 previously unreported cases. By comparing their DNA methylation (DNAm) classifiers with those of healthy controls and other neurodevelopmental disorders characterized by established episignatures, we aimed to create a diagnostic biomarker (episignature) and gain more knowledge of the molecular pathophysiology. We discovered a sensitive and specific DNAm episignature for patients with pathogenic variants in CUL3 and utilized it to reclassify patients carrying a VUS in the CUL3 gene. Comparative epigenomic analysis revealed similarities between NEDAUS and several other rare genetic neurodevelopmental disorders with previously identified episignatures, highlighting the broader implication of our findings. In addition, we performed genotype-phenotype correlation studies to explain the variety in clinical presentation between the cases. We discovered a highly accurate DNAm episignature serving as a robust diagnostic biomarker for NEDAUS. Furthermore, we broadened the phenotypic spectrum by identifying 20 new individuals and confirming five previously reported cases of NEDAUS.

Details

Language :
English
ISSN :
26662477
Volume :
6
Issue :
1
Database :
Directory of Open Access Journals
Journal :
HGG Advances
Publication Type :
Academic Journal
Accession number :
edsdoj.4d2c1e6771da43cd9a0c73ae48b1b4d3
Document Type :
article
Full Text :
https://doi.org/10.1016/j.xhgg.2024.100380